Glioblastoma

Routine surveillance imaging after surgery did not appear to improve outcomes among patients with glioblastoma, according to study results published in World Neurosurgery.

Continued VB-111 monotherapy priming after progression with bevacizumab combination treatment improved survival outcomes among patients with recurrent glioblastoma, according to results of a phase 1/phase 2 study published in Neuro-Oncology.

An observational strategy focusing on preventive measures was effective in preventing cardiac events in low-risk patients with long QT syndrome, researchers reported.

Partial or total resection appeared associated with longer OS compared with biopsy alone among a cohort of adults with brainstem high-grade gliomas, according to study results published in Journal of Neuro-Oncology.

The Mark Foundation for Cancer Research presented grants to six early career scientists who are conducting research projects designed to address unmet needs.

Maximal resection of the contrast-enhanced tumor appeared associated with longer OS among all subgroups of patients with glioblastoma, according to results of a retrospective study published in JAMA Oncology.

The FDA cleared an investigational new drug application for CYNK-001, a natural killer cell therapy, for the treatment of glioblastoma multiforme.

Dolores Hambardzumyan, PhD, MBA, has been appointed senior faculty in the department of neurosurgery and member of The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai.

An international study of glioblastoma revealed a cellular pathway that appears to contribute to glioma stem cell spread and proliferation.

The FDA and European Medicines Agency granted orphan drug designation to zotiraciclib for the treatment of glioma, according to the agent’s manufacturer.